



Shiraj Sen, MD, PhD, and Manojkumar Bupathi, MD, MS, Join Sarah Cannon Research Institute at HealthONE

Sarah Cannon Research Institute at HealthONE is proud to announce the addition of oncologists Shiraj Sen, MD, PhD, and Manojkumar Bupathi, MD, MS, to our clinical trials program.



Shiraj Sen, MD, PhD will serve as associate director of the drug development program with a focus on gastrointestinal cancers and sarcoma. He recently completed his oncology training in 2018 at MD Anderson Cancer Center, where his research focused on overcoming resistance to targeted therapy, optimizing patient selection for immunotherapy phase I trials, and drug development for sarcomas and gastrointestinal cancers.



Manojkumar Bupathi, MD, MS specializes in genitourinary cancers, and he will join our clinic in the coming months on a part-time basis to oversee the treatment of patients with prostate, kidney, bladder, and other genitourinary malignancies on clinical trials. He joined Rocky Mountain Cancer Centers in 2017 after completing his oncology fellowship at Ohio State University, as well as a phase I clinical trials fellowship at MD Anderson Cancer Center.

They join a growing program, which opened in October 2014, with the goal to increase access to clinical trials for these research leaders cancer patients. During the past four years, Sarah Cannon Research Institute at HealthONE has treated more than 450 patients on more than 45 different clinical trials.

About Sarah Cannon Research Institute at HealthONE

Sarah Cannon Research Institute at HealthONE, led by Gerald Falchook, MD, director of the drug development program, conducts innovative cancer clinical trials, bringing patients in the region access to the latest treatments. It's part of a larger research network, with affiliations with hospitals and physicians in the United States and United Kingdom. Sarah Cannon has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Sarah Cannon Research Institute at HealthONE hospitals, physicians and staff, along with the Sarah Cannon team enhance cancer research, diagnosis, treatment and patient-focused services for our patients. For more information about our current trials or for general inquiries, call 720.754.2610.